Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12

Rhea-AI Summary

Bicara Therapeutics (Nasdaq: BCAX) announced that Claire Mazumdar, PhD, MBA, Chief Executive Officer, will present at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026 at 11:15 a.m. PT.

A live webcast will be accessible via the company’s Investor Relations website under Events and Presentations, and a replay will be archived and available after the event.

Key Figures

ATM offering size $150,000,000 Prospectus Supplement 424B5 at-the-market equity program

S-3 shelf capacity $400.0 million Form S-3 shelf referenced in Q3 2025 10-Q

Cash & investments $407.6 million As of September 30, 2025 (Q3 2025 10-Q)

Net loss $36.3 million Q3 2025 net loss reported in 10-Q

Operating expenses $40.7 million Q3 2025 operating expenses per 10-Q

R&D expenses $33.0 million Q3 2025 research and development spend

Shares outstanding 54,781,950 Common shares as of November 5, 2025

Market capitalization $1,032,639,758 Equity value based on pre-news price snapshot

Market Reality Check

$16.38 Last Close

Volume Volume 2,093,523 is 3.07x the 20-day average of 681,752, indicating elevated activity ahead of the conference appearance. high

Technical Price $18.48 is trading above the 200-day MA of $13.2, sitting 10.76% below the 52-week high of $20.7087 and well above the 52-week low of $7.8.

Peers on Argus

BCAX was down 1.96% with strong volume while key biotech peers showed mixed moves: TYRA (-1.48%), ANAB (-1.88%), RIGL (-3.11%), TERN (-4.21%), and PVLA (+0.79%). No peers appeared in the momentum scanner, suggesting BCAX trading was more stock-specific than part of a broad sector rotation.

Common Catalyst One peer, PVLA, reported positive Phase 2 clinical results, indicating stock-specific clinical catalysts rather than a shared conference-related theme across the group.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 01	Clinical data update	Positive	-6.6%	Strong Phase 1b efficacy and disease control data for ficerafusp alfa combo.
Nov 10	Earnings and update	Positive	-4.8%	BTD granted plus solid cash runway and ongoing pivotal trial enrollment.
Oct 13	Regulatory designation	Positive	+4.1%	FDA Breakthrough Therapy Designation for ficerafusp alfa plus pembrolizumab.
Aug 27	Investor conferences	Neutral	-0.9%	Participation in several healthcare investor conferences with webcast access.
Aug 12	Earnings and trials	Positive	+4.8%	Q2 results with strong Phase 1/1b data and robust cash position.

Pattern Detected

Positive clinical and financial updates have produced mixed reactions, with some strong news selling off while other similar updates were rewarded, indicating inconsistent alignment between news quality and short-term price moves.

Recent Company History

Over the last six months, BCAX has advanced ficerafusp alfa with notable milestones, including Breakthrough Therapy Designation on Oct 13, 2025 and multiple positive Phase 1/1b data readouts, such as the 57% ORR and 83% DCR reported on Dec 1, 2025. Financial updates on Aug 12 and Nov 10, 2025 highlighted a strong cash balance funding operations into H1 2029. A prior investor-conference announcement on Aug 27, 2025 generated only a small price move, providing context for today’s J.P. Morgan conference presentation news.

Regulatory & Risk Context

Active S-3 Shelf Registration 2025-10-03

BCAX filed a Form S-3 shelf registration dated October 3, 2025, which references prior SEC filings and clinical data and has seen at least one use via a 424B5 prospectus supplement on November 26, 2025. The shelf provides a framework for issuing securities in the future, as described in the filing.

Market Pulse Summary

This announcement highlights BCAX’s upcoming presentation at the J.P. Morgan 2026 Healthcare Conference, giving management a venue to showcase clinical progress and capital plans. Recent history includes Breakthrough Therapy Designation, strong Phase 1/1b data, and Q3 cash of $407.6 million expected to fund operations into H1 2029. Investors may monitor use of the Form S-3 shelf, the $150,000,000 ATM program, and ongoing insider trading activity alongside future clinical and regulatory updates.

Key Terms

at-the-market offering financial

"is launching an at-the-market offering of up to $150,000,000 of its common stock"

An at-the-market offering is a method companies use to sell new shares of stock directly into the open market over time, rather than all at once. This allows them to raise money gradually, similar to selling small pieces of a product instead of a large batch. For investors, it means the company can access funding more flexibly, but it may also increase the supply of shares and influence the stock’s price.

prospectus supplement regulatory

"[424B5] Bicara Therapeutics Inc. Prospectus Supplement (Debt Securities)"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

form s-3 regulatory

"has filed a registration statement on Form S-3 establishing a shelf for securities"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

registration statement regulatory

"has filed a registration statement on Form S-3 establishing a shelf"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

rule 10b5-1 trading plan regulatory

"The transactions were carried out under a Rule 10b5-1 trading plan adopted on"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

form 10-q regulatory

"including its Form 10-K and amendments. The prospectus discloses clinical data"

A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.

form 8-k regulatory

""[8-K] Bicara Therapeutics Inc. Reports Material Event""

A Form 8-K is a report that companies file with the government to share important news quickly, such as changes in leadership, major business deals, or financial updates. It matters because it helps investors stay informed about significant events that could affect the company's value or stock price.

shelf regulatory

"establishing a shelf for securities and incorporates by reference prior SEC filings"

A shelf is a pre-approved regulatory filing that lets a company register securities in advance so it can sell shares or bonds later without repeating the full approval process each time. For investors it matters because a shelf makes it quick and easy for a company to raise capital when needed — which can fund growth or pay down debt but may also dilute existing shareholders or change the company’s debt profile, similar to having a ready line of credit.

AI-generated analysis. Not financial advice.

BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that Claire Mazumdar, PhD, MBA, Chief Executive Officer, will present at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026 at 11:15 a.m. PT.

A live webcast of the presentation will be accessible through the Investor Relations section of Bicara’s website under Events and Presentations. A replay of the webcast will be archived and available following the event.

About Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara’s lead program, ficerafusp alfa, is a first-in-class bifunctional antibody designed to drive tumor penetration by breaking barriers in the tumor microenvironment that have challenged the treatment of multiple solid tumor cancers. Specifically, ficerafusp alfa combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β). Through this targeted mechanism, ficerafusp alfa reverses the fibrotic and immune-excluded tumor microenvironment driven by TGF-β signaling to enable tumor penetration that drives deep and durable responses. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn and X.

Contacts

Investors
Jenna Cohen
IR@bicara.com

Media
Amanda Lazaro
1AB
Amanda@1abmedia.com

FAQ

When will Bicara Therapeutics (BCAX) present at the J.P. Morgan 2026 Healthcare Conference?

The presentation is scheduled for Monday, January 12, 2026 at 11:15 a.m. PT.

Who will represent Bicara Therapeutics (BCAX) at the J.P. Morgan 2026 Healthcare Conference?

Claire Mazumdar, PhD, MBA, Chief Executive Officer, will present.

How can investors watch Bicara Therapeutics (BCAX) presentation on January 12, 2026?

A live webcast will be available via the company’s Investor Relations site under Events and Presentations.

Will there be a replay of Bicara Therapeutics (BCAX) J.P. Morgan presentation?

Yes, a replay of the webcast will be archived and available on the Investor Relations website after the event.

What topics will Bicara Therapeutics (BCAX) cover at the J.P. Morgan 2026 Healthcare Conference?

The company will present recent developments and corporate updates; specific slide content will be available during the webcast.